Table 3. Patient characteristics and type of EGFR mutation, and EGFR-TKI treatment of EGFR-positive patients.
| Exon 19 | Exon 21 | Exon 18 | ||||
|---|---|---|---|---|---|---|
| del Exon19 | dup Exon19 | Exon19 point mutations (G735S; P753L), non-activating | L858R | V843I, activating but not sensitizing; P848L, non-activating | G719A: 1G719C: 2E709_T710>D: 1complex: 1(E709A + G719S) | |
| n | 26 | 1 | 2 | 12 | 2 | 5 |
| age (mean) | 70.1 | 65.7 | 60.9 | 70.7 | 56.8 | 70.5 |
| female/male | 18/8 | 0/1 | 2/0 | 10/2 | 1/1 | 3/2 |
| smoking status1 | 0: 18;1: 8 | 0: 1 | 1: 12: 1 | 0: 81:4 | 1: 2 | 0: 41: 1 |
| histology | AC 26 | AC 1 | AC 1, SCC 1 | AC 12 | AC 1, NOS 1 | AC 5 |
| TKI treated | 232 | 1 | 2 | 83 | 1 | 5 |
| ECOG4 | 0: 91: 102: 4 | 1: 1 | 1: 2 | 0: 21: 52: 1 | 0: 11: 1 | 0: 31: 2 |
| Stage(UICC 7th ed.) | I-III: 55IV M1a: 5IV M1b: 13 | IV M1b: 1 | IV M1a: 1IV M1b: 1 | IV M1a: 2IV M1b: 6 | IV M1a: 1IV M1b: 1 | IV M1a: 3IV M1b: 2 |
| BRA6 | 6 | 1 | 0 | 4 | 1 | 0 |
| OSS7 | 13 | 1 | 0 | 4 | 0 | 2 |
| other M1b site | 4 | 1 | 1 | 0 | 0 | 0 |
| line TKI | 1st: 152nd: 8 | 1st:1 | 2nd: 2 | 1st: 62nd: 2 | 1st:1 | 1st: 32nd: 2 |
| 1st TKI8 | A 1E 19G 3 | E 1 | E 1G 1 | A 1E 7 | E 1 | A 1E 4 |
| response9 to 1st TKI | CR 1PR 21SD 1 | SD 1 | SD 1PD 1 | PR 8 | SD 1 | PR 4SD 1 |
| progressionon TKI10 | 0: 81: 15 | 1: 1 | 1: 2 | 0: 21: 6 | 1: 1 | 0: 11: 4 |
| brain as site of 1st progression | 3 | 1 | 0 | 2 | 0 | 1 |
| local therapy at progression11 | RT 5 | RT 1 | 0 | RT 2 | RT 1 | RT 1 |
| 1st chemotherapy (carboplatinum-gemcitabine)12 | 7 | 1 | 1 | 4 | 1 | 1 |
| response to first chemotherapy6 | PR 3SD 3PD 1 | PD 1 | PR 1 | PR 2SD 1PD 1 | PR 1n. a. 1 | PD 1 |
| subsequent chemotherapies13 | Pem 5Doce 1Gem 1 | 0 | 0 | Pem 2Pac 1Vin 1 | Pem, Doce | Pem 4Gem 1 |
| response to subsequent chemotherapies6 | PR 2SD 2PD 2, n.a. 1 | - | - | PR 1SD 2PD 1 | PD 1, SD 1 | PR 2SD 3 |
| switch TKI14 | A 4E 1G 1 | A 1 | E 1 | A 2G 1 | - | - |
| response toswitch TKI6 | PD 6 | PR 1 | PD 1 | PD 3 | - | - |
| T790M positive at progression15 | 7 (n=8) | n. a. | n. a. | n. a. | n. a. | 1 (n=3) |
| 3rd gen TKI | 7 | - | - | - | - | 1 |
1 0: never smoker, 1: ex-smoker, 2: smoker.
2 Performance status at start of TKI.
3 BRA: Brain metastases present at start of TKI-therapy.
4 OSS: Bone metastases present at start of TKI-therapy.
5 A: afatinib; E: erlotinib; G: gefitinib.
6 Number of patients with complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD).
7 0: no progression; 1: progression at last observation.
8 RT: radiotherapy (number of patients).
9 EGFR-TKI holiday during platinum doublett chemotherapy.
10 No EGFR-TKI holiday during subsequent mono-chemotherapies. Pem: pemetrexed; Gem: gemcitabine; Doce: docetaxel; Pac: paclitaxel.
11 Number of patients receiving another 1st/2nd generation EGFR-TKI after progression on TKI.
12 Number of patients with positive test result (n: number of patients tested).
13 Three localized stage operable patients (IB, IIB, IIIA) did not have a recurrence and did not receive EGFR-TKI therapy.
14 Five functionally inoperable localized stage patients (IB (3), IIIA, IIIB) received palliative EGFR-TKI therapy.
15 One localized stage operable patient (IIIA) did not have a recurrence and did not receive EGFR-TKI therapy. Four stage IV patients did not receive EGFR-TKI therapy because of poor performance state.